167 related articles for article (PubMed ID: 36724417)
1. Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group.
Abbou S; Klega K; Tsuji J; Tanhaemami M; Hall D; Barkauskas DA; Krailo MD; Cibulskis C; Nag A; Thorner AR; Pollock S; Imamovic-Tuco A; Shern JF; DuBois SG; Venkatramani R; Hawkins DS; Crompton BD
J Clin Oncol; 2023 May; 41(13):2382-2393. PubMed ID: 36724417
[TBL] [Abstract][Full Text] [Related]
2. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.
Sorensen PH; Lynch JC; Qualman SJ; Tirabosco R; Lim JF; Maurer HM; Bridge JA; Crist WM; Triche TJ; Barr FG
J Clin Oncol; 2002 Jun; 20(11):2672-9. PubMed ID: 12039929
[TBL] [Abstract][Full Text] [Related]
3. Molecular Characterization of Circulating Tumor DNA in Pediatric Rhabdomyosarcoma: A Feasibility Study.
Ruhen O; Lak NSM; Stutterheim J; Danielli SG; Chicard M; Iddir Y; Saint-Charles A; Di Paolo V; Tombolan L; Gatz SA; Aladowicz E; Proszek P; Jamal S; Stankunaite R; Hughes D; Carter P; Izquierdo E; Wasti A; Chisholm JC; George SL; Pace E; Chesler L; Aerts I; Pierron G; Zaidi S; Delattre O; Surdez D; Kelsey A; Hubank M; Bonvini P; Bisogno G; Di Giannatale A; Schleiermacher G; Schäfer BW; Tytgat GAM; Shipley J
JCO Precis Oncol; 2022 Oct; 6():e2100534. PubMed ID: 36265118
[TBL] [Abstract][Full Text] [Related]
4. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma.
Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME
Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756
[TBL] [Abstract][Full Text] [Related]
5. Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group.
Hingorani P; Missiaglia E; Shipley J; Anderson JR; Triche TJ; Delorenzi M; Gastier-Foster J; Wing M; Hawkins DS; Skapek SX
Clin Cancer Res; 2015 Oct; 21(20):4733-9. PubMed ID: 26473193
[TBL] [Abstract][Full Text] [Related]
6. Sequential genomic analysis using a multisample/multiplatform approach to better define rhabdomyosarcoma progression and relapse.
de Traux de Wardin H; Dermawan JK; Merlin MS; Wexler LH; Orbach D; Vanoli F; Schleiermacher G; Geoerger B; Ballet S; Guillemot D; Frouin E; Cyrille S; Delattre O; Pierron G; Antonescu CR
NPJ Precis Oncol; 2023 Sep; 7(1):96. PubMed ID: 37730754
[TBL] [Abstract][Full Text] [Related]
7. Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533.
Madanat-Harjuoja LM; Renfro LA; Klega K; Tornwall B; Thorner AR; Nag A; Dix D; Dome JS; Diller LR; Fernandez CV; Mullen EA; Crompton BD
J Clin Oncol; 2022 Sep; 40(26):3047-3056. PubMed ID: 35580298
[TBL] [Abstract][Full Text] [Related]
8. Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
Rudzinski ER; Anderson JR; Chi YY; Gastier-Foster JM; Astbury C; Barr FG; Skapek SX; Hawkins DS; Weigel BJ; Pappo A; Meyer WH; Arnold MA; Teot LA; Parham DM
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28521080
[TBL] [Abstract][Full Text] [Related]
9. [Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children].
Xu N; Duan C; Jin M; Zhang DW; Su Y; Yu T; He LJ; Fu LB; Zeng Q; Wang HM; Zhang WP; Ni X; Ma XL
Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):767-773. PubMed ID: 31594063
[No Abstract] [Full Text] [Related]
10. Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group.
Shulman DS; Klega K; Imamovic-Tuco A; Clapp A; Nag A; Thorner AR; Van Allen E; Ha G; Lessnick SL; Gorlick R; Janeway KA; Leavey PJ; Mascarenhas L; London WB; Vo KT; Stegmaier K; Hall D; Krailo MD; Barkauskas DA; DuBois SG; Crompton BD
Br J Cancer; 2018 Aug; 119(5):615-621. PubMed ID: 30131550
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical detection of PAX-FOXO1 fusion proteins in alveolar rhabdomyosarcoma using breakpoint specific monoclonal antibodies.
Azorsa DO; Bode PK; Wachtel M; Cheuk ATC; Meltzer PS; Vokuhl C; Camenisch U; Khov HL; Bode B; Schäfer BW; Khan J
Mod Pathol; 2021 Apr; 34(4):748-757. PubMed ID: 33299109
[TBL] [Abstract][Full Text] [Related]
12. Detection and clinical significance of bone marrow involvement in patients with rhabdomyosarcoma.
Krsková L; Mrhalová M; Hilská I; Sumerauer D; Drahokoupilová E; Múdry P; Kodet R
Virchows Arch; 2010 May; 456(5):463-72. PubMed ID: 20405298
[TBL] [Abstract][Full Text] [Related]
13. Germline genetic variants and pediatric rhabdomyosarcoma outcomes: a report from the Children's Oncology Group.
Martin-Giacalone BA; Richard MA; Scheurer ME; Khan J; Sok P; Shetty PB; Chanock SJ; Li SA; Yeager M; Marquez-Do DA; Barkauskas DA; Hall D; McEvoy MT; Brown AL; Sabo A; Scheet P; Huff CD; Skapek SX; Hawkins DS; Venkatramani R; Mirabello L; Lupo PJ
J Natl Cancer Inst; 2023 Jun; 115(6):733-741. PubMed ID: 36951526
[TBL] [Abstract][Full Text] [Related]
14. Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Heske CM; Chi YY; Venkatramani R; Li M; Arnold MA; Dasgupta R; Hiniker SM; Hawkins DS; Mascarenhas L
Cancer; 2021 Mar; 127(6):946-956. PubMed ID: 33216382
[TBL] [Abstract][Full Text] [Related]
15. Relationship of DNA methylation to mutational changes and transcriptional organization in fusion-positive and fusion-negative rhabdomyosarcoma.
Sun W; Chatterjee B; Shern JF; Patidar R; Song Y; Wang Y; Walker RL; Pawel BR; Linardic CM; Houghton P; Hewitt SM; Edelman DC; Khan J; Meltzer PS; Barr FG
Int J Cancer; 2019 Jun; 144(11):2707-2717. PubMed ID: 30565669
[TBL] [Abstract][Full Text] [Related]
16. Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group.
Arnold MA; Anderson JR; Gastier-Foster JM; Barr FG; Skapek SX; Hawkins DS; Raney RB; Parham DM; Teot LA; Rudzinski ER; Walterhouse DO
Pediatr Blood Cancer; 2016 Apr; 63(4):634-9. PubMed ID: 26756883
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children's Oncology Group.
Rodeberg DA; Garcia-Henriquez N; Lyden ER; Davicioni E; Parham DM; Skapek SX; Hayes-Jordan AA; Donaldson SS; Brown KL; Triche TJ; Meyer WH; Hawkins DS
J Clin Oncol; 2011 Apr; 29(10):1304-11. PubMed ID: 21357792
[TBL] [Abstract][Full Text] [Related]
18. Predicting Molecular Subtype and Survival of Rhabdomyosarcoma Patients Using Deep Learning of H&E Images: A Report from the Children's Oncology Group.
Milewski D; Jung H; Brown GT; Liu Y; Somerville B; Lisle C; Ladanyi M; Rudzinski ER; Choo-Wosoba H; Barkauskas DA; Lo T; Hall D; Linardic CM; Wei JS; Chou HC; Skapek SX; Venkatramani R; Bode PK; Steinberg SM; Zaki G; Kuznetsov IB; Hawkins DS; Shern JF; Collins J; Khan J
Clin Cancer Res; 2023 Jan; 29(2):364-378. PubMed ID: 36346688
[TBL] [Abstract][Full Text] [Related]
19. PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma.
Hanna JA; Garcia MR; Go JC; Finkelstein D; Kodali K; Pagala V; Wang X; Peng J; Hatley ME
Cell Death Dis; 2016 Jun; 7(6):e2256. PubMed ID: 27277678
[TBL] [Abstract][Full Text] [Related]
20. Early detection of the PAX3-FOXO1 fusion gene in circulating tumor-derived DNA in a case of alveolar rhabdomyosarcoma.
Eguchi-Ishimae M; Tezuka M; Kokeguchi T; Nagai K; Moritani K; Yonezawa S; Tauchi H; Tokuda K; Ishida Y; Ishii E; Eguchi M
Genes Chromosomes Cancer; 2019 Aug; 58(8):521-529. PubMed ID: 30739374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
